Perilous Reversal Stock: ZIOPHARM Oncology (ZIOP)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified ZIOPHARM Oncology ( ZIOP) as a "perilous reversal" (up big yesterday but down big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified ZIOPHARM Oncology as such a stock due to the following factors:

  • ZIOP has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $33.6 million.
  • ZIOP has traded 141,663 shares today.
  • ZIOP is down 3.1% today.
  • ZIOP was up 14% yesterday.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ZIOP with the Ticky from Trade-Ideas. See the FREE profile for ZIOP NOW at Trade-Ideas

More details on ZIOP:

ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Currently there are 2 analysts that rate ZIOPHARM Oncology a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for ZIOPHARM Oncology has been 3.9 million shares per day over the past 30 days. ZIOPHARM Oncology has a market cap of $1.2 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.71 and a short float of 27.9% with 9.25 days to cover. Shares are up 111.4% year-to-date as of the close of trading on Friday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Good, the Bad and the Ugly; What Troubles Me: Doug Kass' Views

Judgment Day; The Good, the Bad and the Ugly: Doug Kass' Views

Twitter, Netflix, MetLife: Doug Kass' Views

Don't Overlook Ziopharm Oncology